Forte Biosciences, Inc.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing FB102, its lead product candidate, for immune-mediated diseases. The company has no approved products and no product revenue, so its value is tied primarily to advancing FB102 through preclinical and clinical development toward regulatory approval.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaThe company’s main therapeutic asset under development for immune-mediated indications such as celiac disease and vitiligo.
Research, trial execution, and data generation needed to advance FB102 through development milestones.
Outsourced drug substance and drug product manufacturing, plus supply chain support for studies.
Potential collaboration, license, milestone, and royalty economics if the company partners assets.
Asiakkaat
Forte does not currently sell approved products, so it has no commercial customer base today. Its future customers would likely be physicians, patients, and third-party payors in the immune-mediated disease markets if FB102 is approved and commercialized. In the near term, the company’s key external counterparties are CROs, CMOs, and other service providers that support development and manufacturing.
Would use FB102 if approved for immune-mediated diseases such as celiac disease or vitiligo.
Would determine reimbursement and access if the product reaches commercialization.
Provide outsourced trial execution and manufacturing services that enable development.
Could provide funding, development support, or commercialization rights through deals.
Strategia
Forte’s strategy is to concentrate resources on FB102 after discontinuing FB-401, reflecting a narrower and more capital-efficient development focus. The company is prioritizing clinical progress, manufacturing readiness, and regulatory execution while preserving optionality for future collaborations or licensing if needed. Because it is early stage and capital constrained, execution speed and data quality are central to its competitive position.
The company’s prospects are highly dependent on FB102 succeeding in early-stage studies and later trials.
Drug supply and cGMP readiness are required to continue trials and prepare for any future commercialization.
The company will need funding to continue development and may use collaborations to reduce dilution or share risk.
Maantiede
Forte is a U.S.-based company and its disclosures emphasize exposure to U.S. capital markets, FDA regulation, and domestic clinical development activity. The company also notes global macro and geopolitical risks, but it does not disclose meaningful country-level revenue because it has no product sales. Its operational footprint is therefore concentrated in the United States, with outsourced research and manufacturing potentially involving third parties in other regions.
Riskit
Forte is a pre-revenue biotech with a single lead asset, so clinical failure, financing shortfalls, or regulatory setbacks could materially impair the business. Its reliance on third parties for trials and manufacturing, plus patent and market-acceptance risk, creates a high-risk development profile typical of early-stage drug companies. Public-market volatility, Nasdaq compliance, and internal control issues add additional financial and trading risk.
- Clinical development failure of FB102Vaikutus: KriittinenTodennäköisyys: Korkea
The company is almost entirely dependent on one lead candidate, and early data may not predict later-stage success.
Kohdistuu: FB102 celiac disease and vitiligo programs
- Financing risk and going-concern pressureVaikutus: KriittinenTodennäköisyys: Korkea
The company has no product revenue and will need additional capital to continue development.
Kohdistuu - Third-party manufacturing and trial execution riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Forte relies on CROs and CMOs, so delays or quality issues can disrupt timelines and increase costs.
Kohdistuu - Intellectual property and patent riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Without strong patent protection, competitors could develop similar therapies and erode future value.
Kohdistuu: FB102 and related technology
- Nasdaq compliance and stock volatilityVaikutus: KeskitasoTodennäköisyys: Korkea
Prior bid-price noncompliance and volatile trading can reduce market access and investor confidence.
Kohdistuu: Public equity financing and liquidity
- Public health and macroeconomic disruptionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Inflation, rate pressure, geopolitical conflict, and epidemics can delay trials and make financing harder.
Kohdistuu: Development timelines and capital markets
Kirjanpito
Harkinnanvaraiset erätClinical and manufacturing costs are recognized as work is performed, so estimates affect quarterly expense timing.
Vaikutus: Can materially change reported operating loss from quarter to quarter
Management estimates percentage of completion for outsourced studies and manufacturing.
Vaikutus: Affects R&D expense and accrued liabilities
Non-refundable prepayments for future R&D services are deferred until services are received.
Vaikutus: Can shift expense recognition across reporting periods
Other income, net is mainly interest income on cash balances, offset by minor taxes and FX.
Vaikutus: Can partially offset operating losses but is not core operating performance
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Fortrea Holdings Inc.
FTRE · Services-Medical Laboratories
Solid Biosciences Inc.
SLDB · Biological Products, (No Diagnostic Substances)
Neurogene Inc.
NGNE · Pharmaceutical Preparations
Fortress Biotech, Inc.
FBIOP · Pharmaceutical Preparations
Tyra Biosciences, Inc.
TYRA · Pharmaceutical Preparations
Inmune Bio, Inc.
INMB · Biological Products, (No Diagnostic Substances)
Päivitetty: 24.9.2026